Everything below concerns Immune modulation. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-07-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
| Property | Value | Notes |
|---|---|---|
| Amino acid length | 28 residues | Single chain with an acetylated N-terminus |
| Molecular mass | Approximately 3,108 Da | Small shifts occur with counter-ion and water content |
| Isoelectric point | Around 3.5 | Low value follows from the many acidic residues |
| Parent molecule | N-terminal region of prothymosin alpha | Free circulating form in humans is not firmly established |
| Common synonyms | Thymalfasin; T alpha 1 | Older literature also uses the full spelled-out form |
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.
Stability depends on temperature, pH, and the number of freeze-thaw events the sample has experienced. Freeze-dried material is commonly held at -20 °C or colder, while reconstituted liquid is kept cold and used within a short window. Extreme pH and prolonged light exposure can promote deamidation, oxidation, or aggregation, particularly at asparagine and methionine positions. Adsorption to container walls can lower the measured concentration of a dilute solution even when the peptide molecules themselves remain intact.
== United States == In the United States, the Food and Drug Administration (FDA) has determined that while such tests qualify as medical devices, these products could enter the market without prior approval from the agency. In 2014, the FDA announced that it would start regulating some LDTs. In general, however, it has not done so, as of April 2019. As LDTs do not require FDA 510(k) clearance required by other diagnostic tests, they have been viewed as a regulatory loophole by opponents.
=== C-Linked glycans === Of the three linkages the least common and least understood are C-linked glycans. The C-linkage refers to the covalent attachment of mannose to a tryptophan residue. An example of a C-linked glycan is α-mannosyl tryptophan.
=== Effects on the liver === Long-term use of kava has been associated with potential hepatotoxicity; however, the evidence remains inconclusive. Some kava extracts have demonstrated to be hepatotoxic. Concerns about this prompted warnings from health authorities in the United States, Australia, and Canada and led to kava being omitted from the US Pharmacopeia. The potential causes include contamination with toxic alkaloids from kava leaves and stems, differences in traditional versus commercial preparations, drug interactions affecting liver enzymes, and genetic variations in metabolism among populations. While kava appears safe in traditional South Pacific use, caution is advised, especially during pregnancy, for people with preexisting liver conditions, or when combined with alcohol consumption, prescription drugs or dietary supplements. The risk is higher with alcoholic or acetonic extracts, or concentrated forms like pills. Water-based kava extracts in moderate doses are considered safer, but should not be consumed with alcohol, particularly by those with a history of liver issues.
Gram-positive aerobes Methicillin-susceptible Staphylococcus species (including Staphylococcus aureus) Streptococcus agalactiae Streptococcus pneumoniae (not established for penicillin-resistant strains) Gram-negative aerobes Escherichia coli Haemophilus influenzae Klebsiella pneumoniae Moraxella catarrhalis Proteus mirabilis Anaerobes: Clostridium species (excluding Clostridioides difficile) Eubacterium species Fusobacterium species Peptostreptococcus species Porphyromonas asaccharolytica Prevotella species The US Food and Drug Administration (FDA) label specifies activity against additional anaerobes: Bacteroides distasonis Bacteroides fragilis Bacteroides ovatus Bacteroides thetaiotaomicron Bacteroides uniformis
In practice, Sucre depended so much on the orders of Bolívar that he was quickly seen by Peruvians and people of the River Plate as a puppet or bridgehead of the Liberator in the continental south, a “proconsul of the Bolivian empire”. "You can't think of the multitude of papers that come from Peru to upset Bolivia. Until today they have had no influence, but perhaps in the long run they will do something. the Argentines. I am happy about this because I will be able to carry out the project of the federation of Chile, Bolivia and Buenos Aires." Subsequently, Sucre would have carried out an intense campaign to seize Arica from Peru and give it to Bolivia for its annexation to a natural outlet to the sea, proposing it in October 1826, he also warned Bolívar, during one of his letters of the year 1828, about the danger that Peru would be for Gran Colombia: "If Peru conquers Bolivia and keeps it, the South of Colombia (current Ecuador) runs a thousand and a thousand risks." To this is added the testimony of the Argentine minister M. Bustos, who on October 27, 1828, said in the Buenos Aires newspaper "El Tiempo" that Sucre and Gamarra had put together a plan to make Bolívar the Emperor of South America, separating Puno, Arequipa and Cuzco from the Republic of Peru, something Bolívar was aware of but did not want to make a false step. The centralism of the capital only produced new supporters of federalism and, in some cases, of secession, in Arequipa.
Sources: en.wikipedia.org
The idea of initiating the institute was elaborated in 1960 via high council of science, owing to the magnitude of schistosomiasis problem in Egypt specially in the rural population and its impact on the socioeconomic life. The objective of the institute was to tackle this diseases from all its aspects : control, diagnosis and management. In 1960, Ahmed Hafez Mousa, the real originator of the institute and one of the world's pioneers in the field of Tropical Medicine was charged to fulfill this idea. He appointed the Tropical Medicine Department at Kasr El Aini, Faculty of Medicine a preliminary location for a small nuclear start of this project. This was followed by the establishment of a "Laboratory for Schisosomiasis Research" in the chemistry building of the National Research Center. In April 1962, the foundation stone of the institute was implemented at Warak El Hader's village in Giza governorate. Meanwhile, the building of the institute was constructed by Egyptian Government, the laboratories and hospital were equipped through an agreement between the governments of Federal Republic of Germany and Egypt in 1964. The TBRI was built on 25,000 m2 formed of four main buildings in front of the west bank of the Great River Nile in Giza governorate. In 1977 The institute construction was accomplished, and opened for public, headed by Ali Zain El-Abdeen. in 1979. Ahmad Algarim became the head of the institute, and until 1987. In 1987, Aly Zain Al- Abdeen headed the institute and till his retirement in 1994.
They can also be made by the reaction of Lawesson's reagent with esters or by treating pinner salts with hydrogen sulfide. Various thionoesters may be prepared through the transesterification of an existing methyl thionoester with an alcohol under base-catalyzed conditions.
== Structure == Lumican is a proteoglycan Class II member of the small leucine-rich proteoglycan (SLRP) family that includes decorin, biglycan, fibromodulin, keratocan, epiphycan, and osteoglycin. Like the other SLRPs, lumican has a molecular weight of about 40 kilodaltons and has four major intramolecular domains:
The chemical structure of penicillin was first proposed by Edward Abraham in 1942 and was later confirmed in 1945 using X-ray crystallography by Dorothy Crowfoot Hodgkin, who was also working at Oxford. She later in 1964 received the Nobel Prize in Chemistry for this and other structure determinations. The chemist John C. Sheehan at the Massachusetts Institute of Technology (MIT) completed the first chemical synthesis of penicillin in 1957. Sheehan had started his studies into penicillin synthesis in 1948, and during these investigations developed new methods for the synthesis of peptides, as well as new protecting groups—groups that mask the reactivity of certain functional groups. Although the initial synthesis developed by Sheehan was not appropriate for mass production of penicillins, one of the intermediate compounds in Sheehan's synthesis was 6-aminopenicillanic acid (6-APA), the nucleus of penicillin. 6-APA was discovered by researchers at the Beecham Research Laboratories (later the Beecham Group) in Surrey in 1957 (published in 1959). Attaching different groups to the 6-APA 'nucleus' of penicillin allowed the creation of new forms of penicillins which are more versatile and better in activity.
Sources: en.wikipedia.org
=== STEM feed === In March 2023, TikTok introduced a dedicated feed for science, technology, engineering, and mathematics (STEM) content. It works with Common Sense Networks to check for safety and age appropriateness and with the Poynter Institute for reliability of information.
==== Sucrase ==== Function: Sucrase is a stomachs related protein that mobilizes hydrolysis to convert sucrose into glucose and fructose. Clinical Significance: Low amounts of Sucrose also known as Sucrose intolerance happens when sucrose isn't being discharged in the small digestive tract. A result of this is extra gas.
Protein folding must be thermodynamically favorable within a cell in order for it to be a spontaneous reaction. Since it is known that protein folding is a spontaneous reaction, then it must assume a negative Gibbs free energy value. Gibbs free energy in protein folding is directly related to enthalpy and entropy. For a negative delta G to arise and for protein folding to become thermodynamically favorable, then either enthalpy, entropy, or both terms must be favorable.
Sources: en.wikipedia.org
It is usually described as an immunomodulatory peptide rather than a classic circulating hormone. No endocrine gland is known to release it as a primary secretory product, and its measured presence in blood is not firmly established.
Prothymosin alpha is a much larger acidic protein, roughly 111 to 113 residues long, and the thymosin alpha-1 sequence matches its N-terminal region. The small peptide is therefore best understood as a fragment of that parent protein rather than a separate gene product.
Trials and clinical reports have examined chronic hepatitis B and C, use as a vaccine adjuvant, and supportive treatment in some immunodeficiency and oncology settings. Results vary by indication, and regulatory approval differs between countries.
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.